Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now

In the first quarter of 2024, the Genomics/NGS group reported higher sales of universal library prep kits for use with third-party next-generation sequencers. The QDI business continued to see solid demand trends, setting out an optimistic CER growth outlook for the full year. Furthermore, QIAGEN continuously integrates AI technology into the QDI portfolio, launching an AI-driven knowledge base for drug discovery and enhancing QCI Interpret software for rare disease gene coverage. Strategic Collaborations t ...